Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021

Felix C Ringshausen; Annette Sauer-Heilborn; Tina Büttner; Anna-Maria Dittrich; Nicolaus Schwerk; Fabio Ius; Lutz Nährlich; Tobias Welte; Mark Greer

doi:10.1183/13993003.01402-2022

Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021

Eur Respir J. 2023 Jan 12;61(1):2201402. doi: 10.1183/13993003.01402-2022. Print 2023 Jan.

Authors

Felix C Ringshausen^{1

2

3}, Annette Sauer-Heilborn^{4

2

3}, Tina Büttner^{4

2

3

5}, Anna-Maria Dittrich^{2

5}, Nicolaus Schwerk^{2

5}, Fabio Ius^{2

6}, Lutz Nährlich⁷, Tobias Welte^{4

2

3}, Mark Greer^{4

2

3}

Affiliations

¹ Department of Respiratory Medicine, Hannover Medical School (MHH), Hannover, Germany Ringshausen.Felix@mh-hannover.de.
² Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
³ European Reference Network on Rare and Complex Respiratory Diseases (ERN-LUNG), Frankfurt, Germany.
⁴ Department of Respiratory Medicine, Hannover Medical School (MHH), Hannover, Germany.
⁵ Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School (MHH), Hannover, Germany.
⁶ Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School (MHH), Hannover, Germany.
⁷ Department of Pediatrics, Justus-Liebig-University Giessen, and Universities of Giessen and Marburg Lung Center, German Center for Lung Research (DZL), Giessen, Germany.

PMID: 36517178
DOI: 10.1183/13993003.01402-2022

No abstract available

Publication types

Letter

MeSH terms

Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Cystic Fibrosis* / genetics
Humans
Lung Transplantation*
Mutation

Substances

elexacaftor
ivacaftor
tezacaftor
Cystic Fibrosis Transmembrane Conductance Regulator